Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$2.23
-2.6%
$2.05
$1.50
$6.25
$8.24M1.8769,619 shs58,094 shs
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$7.34
-6.1%
$5.89
$3.18
$100.46
$8.62M1.88908,050 shs664,458 shs
GRDX
Entero Therapeutics
$3.39
+18.8%
$2.30
$1.06
$5.84
$11.42M1.38121,165 shs106,469 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.14
-3.4%
$2.20
$0.85
$6.92
$1.97M1.28116,313 shs38,269 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
+2.69%+1.78%+1.78%+18.65%+18.65%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
+29.47%+111.92%+46.17%-16.87%-89.93%
GRDX
Entero Therapeutics
+11.33%+13.55%+31.94%-2.06%+284,999,900.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-0.84%+7.27%-46.61%-61.06%-61.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$2.23
-2.6%
$2.05
$1.50
$6.25
$8.24M1.8769,619 shs58,094 shs
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$7.34
-6.1%
$5.89
$3.18
$100.46
$8.62M1.88908,050 shs664,458 shs
GRDX
Entero Therapeutics
$3.39
+18.8%
$2.30
$1.06
$5.84
$11.42M1.38121,165 shs106,469 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.14
-3.4%
$2.20
$0.85
$6.92
$1.97M1.28116,313 shs38,269 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
+2.69%+1.78%+1.78%+18.65%+18.65%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
+29.47%+111.92%+46.17%-16.87%-89.93%
GRDX
Entero Therapeutics
+11.33%+13.55%+31.94%-2.06%+284,999,900.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-0.84%+7.27%-46.61%-61.06%-61.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.50
ReduceN/AN/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
2.00
Hold$30.00308.50% Upside
GRDX
Entero Therapeutics
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SNOA, CELZ, GRDX, and ERNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
Initiated CoverageBuy$30.00
4/29/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
DowngradeSell (D-)Sell (E+)
4/21/2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
Reiterated RatingSell (E+)
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$6K1,374.05N/AN/A$2.04 per share1.09
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$580K14.81N/AN/A$7.64 per share0.96
GRDX
Entero Therapeutics
$40K284.51N/AN/A($2.45) per share-1.38
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$17.72M0.11N/AN/A$2.73 per share0.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$5.99M-$2.59N/AN/AN/AN/A-85.62%-82.36%5/8/2026 (Estimated)
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$14.08M-$75.47N/AN/AN/AN/A-1,262.77%-228.54%N/A
GRDX
Entero Therapeutics
-$18.06M-$1.69N/AN/AN/AN/A-461.02%-14.72%N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$2.04N/AN/AN/A-19.04%-42.56%-11.97%7/15/2026 (Estimated)

Latest SNOA, CELZ, GRDX, and ERNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2026N/A
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$0.39N/AN/AN/A$0.00 millionN/A
5/1/2026Q4 2025
GRDX
Entero Therapeutics
N/A-$1.88N/A-$1.88N/AN/A
3/20/2026Q4 2025
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$0.37-$0.80-$0.43-$0.80N/A$0.00 million
2/10/2026Q3 2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.29-$0.35-$0.06-$0.48$5.47 million$4.35 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/AN/AN/AN/AN/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/A
GRDX
Entero Therapeutics
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/A
25.96
25.96
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A
1.01
1.01
GRDX
Entero Therapeutics
N/A
2.62
2.62
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
2.88
2.00
CompanyEmployeesShares OutstandingFree FloatOptionable
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
53.70 million3.63 millionNot Optionable
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
101.17 million1.15 millionNo Data
GRDX
Entero Therapeutics
93.36 million3.34 millionN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.73 million1.31 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals reports higher revenue
Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf

New MarketBeat Followers Over Time

Media Sentiment Over Time

Creative Medical Technology stock logo

Creative Medical Technology NASDAQ:CELZ

$2.23 -0.06 (-2.62%)
As of 11:06 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Ernexa Therapeutics stock logo

Ernexa Therapeutics NASDAQ:ERNA

$7.34 -0.48 (-6.09%)
As of 11:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Entero Therapeutics NASDAQ:GRDX

$3.39 +0.54 (+18.84%)
As of 11:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$1.14 -0.04 (-3.39%)
As of 11:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.